Sergio A. Giralt, MD, FACP and Selina Luger, MD, FRCPC - Achieving Next-Level Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MQE865. CME credit will be available until December 31, 2024.

Achieving Next-Level Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and the HealthTree Foundation for Acute Myeloid Leukemia.

Support
This activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.

Disclosures
Sergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Jazz Pharmaceuticals, Inc.; Johnson & Johnson, Inc.; Kite Pharma; Novartis Pharmaceuticals Corporation; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Actinium Pharmaceuticals, Inc.; Amgen Inc.; Celgene Corporation; Johnson & Johnson, Inc.; Miltenyi Biotec; Sanofi; and Takeda Pharmaceutical Company Limited.

Selina Luger, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Amgen Inc.; Bristol Myers Squibb; and Marker Therapeutics, Inc.
Grant/Research Support from Onconova Therapeutics, Inc.
Speaker for Amgen Inc.

Pinkal Desai, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Laboratories.

Ghayas Issa, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Kura Oncology, Inc. and Novartis Pharmaceuticals Corporation.
Grant/Research Support from Cullinan Oncology, Inc; Kura Oncology, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Syndax.

Tapan Kadia, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Daiichi Sankyo Inc.; Genentech, Inc.; Genzyme Corporation; Jazz Pharmaceuticals, Inc.; Liberum Capital Limited; Novartis Pharmaceuticals Corporation; Pfizer; PinotBio, Inc.; Pulmotect, Inc.; Sanofi; Servier Laboratories.
Grant/Research Support from AbbVie; Amgen Inc.; Ascentage Pharma Group; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Cellenkos Inc.; Cyclacel Pharmaceuticals, Inc.; Delta-Fly Pharma, Inc.; Genentech, Inc.; GenFleet Therapeutics; GlycoMimetics; Iterion Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Pfizer; Pulmotect, Inc.; Regeneron Pharmaceuticals Inc.; and SELLAS Life Sciences Group. Grant/Research Support Paid to Institution.
Speakers Bureau participant with Biologix USA, Inc.; CURE Pharmaceutical; and Hikma Pharmaceuticals.
Honorarium from Genzyme Corporation.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.